迪哲医药：源头创新小分子创新药迈向全球

国泰君安11-12

本报告导读：公司立足源头创新，核心产品迈向全球市场。舒沃替尼、戈利昔替尼陆续步入收获期，早期管线充沛，潜力十足，首次覆盖，给予增持评级。投资要点：首次覆盖，给予增持评级。公司立足源头创新，打造具备全球竞争力的差异化管线，核心产品舒沃替尼、戈利昔替尼陆续步入收获期。预测公司2024-2026 年营业收入分别为4.67/9.73/15.82 亿元。结合绝对估值法及相对估值法，给予目标价61.82 元...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2482703301?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-12 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2482703301","market":"sh","top_or_hot":-1,"title":"迪哲医药：源头创新 小分子创新药迈向全球","media":"国泰君安","content":"<div>\n<p>本报告导读：公司立足源头创新，核心产品迈向全球市场。舒沃替尼、戈利昔替尼陆续步入收获期，早期管线充沛，潜力十足，首次覆盖，给予增持评级。投资要点：首次覆盖，给 予增持评级。公司立足源头创新，打造具备全球竞争力的差异化管线，核心产品舒沃替尼、戈利昔替尼陆续步入收获期。预测公司2024-2026 年营业收入分别为4.67/9.73/15.82 亿元。结合绝对估值法及相对估值法，给予目标价61.82 元...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111220061995be182a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>迪哲医药：源头创新 小分子创新药迈向全球</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n迪哲医药：源头创新 小分子创新药迈向全球\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-12 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111220061995be182a&s=b><strong>国泰君安</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>本报告导读：公司立足源头创新，核心产品迈向全球市场。舒沃替尼、戈利昔替尼陆续步入收获期，早期管线充沛，潜力十足，首次覆盖，给予增持评级。投资要点：首次覆盖，给 予增持评级。公司立足源头创新，打造具备全球竞争力的差异化管线，核心产品舒沃替尼、戈利昔替尼陆续步入收获期。预测公司2024-2026 年营业收入分别为4.67/9.73/15.82 亿元。结合绝对估值法及相对估值法，给予目标价61.82 元...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111220061995be182a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688192","symbol_name":"迪哲医药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111220061995be182a&s=b","article_id":"2482703301","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111220061995be182a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2482703301","pubTimestamp":1731340800,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"舒沃替尼、戈利昔替尼陆续步入收获期，早期管线充沛，潜力十足，首次覆盖，给予增持评级。公司立足源头创新，打造具备全球竞争力的差异化管线，核心产品舒沃替尼、戈利昔替尼陆续步入收获期。舒沃替尼突破肺癌难治突变，全球市场渐入收获期。戈利昔替尼取得PTCL 领域新突破，提供治疗新选择。戈利昔替尼于2024 年6 月在中国市场获批上市，进一步提供业绩增量，在海外亦有望迈向商业化阶段。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688192":"迪哲医药","BK0239":"医药制造"},"translate_title":"Dizhe Pharmaceutical: Source innovation, small molecule innovative drugs go global","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688192":1},"content_text":"本报告导读：公司立足源头创新，核心产品迈向全球市场。舒沃替尼、戈利昔替尼陆续步入收获期，早期管线充沛，潜力十足，首次覆盖，给予增持评级。投资要点：首次覆盖，给 予增持评级。公司立足源头创新，打造具备全球竞争力的差异化管线，核心产品舒沃替尼、戈利昔替尼陆续步入收获期。预测公司2024-2026 年营业收入分别为4.67/9.73/15.82 亿元。结合绝对估值法及相对估值法，给予目标价61.82 元。首次覆盖，给予增持评级。舒沃替尼突破肺癌难治突变，全球市场渐入收获期。EGFR ex20ins系NSCLC 难治突变，传统EGFR-TKI 疗效有限，临床用药短缺。舒沃替尼精准抑制该EGFR 难治突变亚型，获中美双突破性疗法认定，二线注册性临床WU-KONG6（国内）、WU-KONG1B（国际）均展现全球最佳潜力，国内获批上市后迎来高速放量，在美国已申报上市；此外，舒沃替尼进一步开展国际多中心注册性临床，拓展一线EGFR ex20ins 市场，充分发挥同类最优潜力。舒沃替尼于2023年8 月国内获批，公司2024Q1-Q3 实现收入3.38 亿元，同比+744%，主要系该产品推动，放量的高速增长态势有望维持。戈利昔替尼取得PTCL 领域新突破，提供治疗新选择。PTCL 的治疗高度依赖化疗，后线治疗缺乏有效手段，复发/难治型患者生存状况较差。戈利昔替尼为新一代JAK1 抑制剂，基于源头创新机制，针对r/r PTCL 取得临床突破，国际多中心注册性临床JACKPOT8 研究取得优异疗效，临床获益显著优于现有的其他疗法，已进入临床指南。戈利昔替尼于2024 年6 月在中国市场获批上市，进一步提供业绩增量，在海外亦有望迈向商业化阶段。早期研发管线充沛，持续产出全球首创分子。DZD8586 为公司开发的全球首创LYN/BTK 抑制剂，早期数据亮眼，针对B-NHL 的DLBCL、CLL/SLL 等领域均有广阔的应用潜力，且提供克服BTK抑制剂耐药的新途径，有望填补临床空白。此外，DZD6008、DZD2269、DZD1516 等多款早期临床管线持续推进，有望陆续验证全球首创或全球最优分子潜力。风险提示。临床试验进展不及预期风险；新药研发失败风险；市场推广及销售不及预期风险；国际化业务进展不及预期风险。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482703301"}

迪哲医药：源头创新 小分子创新药迈向全球

精彩评论

迪哲医药：源头创新小分子创新药迈向全球